Haisco Pharmaceutical Group Co., Ltd. Overview
Pro stress-test →Haisco Pharmaceutical Group is a diversified Chinese pharmaceutical manufacturer and R&D company specializing in injectable drugs, with a broad portfolio spanning anesthesia, analgesia, endocrinology, oncology, and liver disease treatments. Founded in 2000 and publicly listed since 2012, the company focuses on the domestic Chinese market with a strong emphasis on innovation in specialized drug formulations.
Strategic Profile
Pro stress-test →Haisco differentiates itself through specialized expertise in high-value injectable medications and multiple late-stage drug candidates in development. The company leverages its manufacturing capabilities and R&D pipeline to address underserved therapeutic areas including non-alcoholic fatty liver disease, advanced solid tumors, and chronic respiratory conditions.
Competitive Landscape
Pro stress-test →Haisco competes within the fragmented Chinese pharmaceutical market against both state-owned enterprises and private companies. Key competitors include Zhejiang Huahai Pharmaceutical and other regional specialty pharmaceutical manufacturers. The company's focus on high-value injectable formulations and specialized therapeutics provides differentiation from commodity drug producers.
Industry Context
Haisco Pharmaceutical Group Co., Ltd. operates in Pharmaceutical Manufacturing & Development.
Key facts
Founded: 2000 · Headquarters: Shannan, China · Employees: 5,337 · Market cap: 60.03B CNY